Project Grant R01CA291887

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) is focused on developing a "next-generation" precision adoptive T cell therapy approach to treat pediatric high-grade gliomas. The $474,656 award will fund research to evaluate the safety, efficacy, and immunological effects of this therapy in preclinical models, determine the capacity to isolate and expand antigen-specific T cells from pediatric patients, and conduct a Phase 1...

This Project Grant award of $717,802, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to elucidate the cellular and molecular mechanisms underlying the development of a rare and aggressive form of brain cancer known as H3.3G34-mutant high-grade glioma (HGG-G34). The key objectives are to: 1) unravel the transcriptional targets of the...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a 24-month, $430,375 Project Grant (CFDA 93.853) to Emory University to develop human organoid models for pediatric high-grade gliomas (PHGGs). The research aims to 1) create PHGG organoid models using human patient-derived cancer stem cells and 2) model how interactions between PHGG cells and the human neural microenvironment affect responses to tyrosine kinase inhibitors and other anti-tumor drugs. The goal is to...

This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $1,390,720 to The Leland Stanford Junior University (Stanford University) to develop an optimized chimeric antigen receptor (CAR) T-cell therapy targeting cerebroglycan (GPC2) for the treatment of medulloblastoma, the most common malignant brain tumor in children. The key objectives are to: 1) Define the optimal approach to overexpress the transcription factor cJun in...

This Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on understanding, treating, and potentially preventing pediatric brain tumors, specifically diffuse midline gliomas (DMGs) harboring the H3K27M mutation. The $443,354 award to the University of Pittsburgh aims to investigate how metabolic pathways...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop metabolic therapy and imaging for diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The research aims to identify and target the vulnerabilities induced by the H3K27M mutation that drives DMGs, specifically inhibiting the enzymes...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The General Hospital Corporation, doing business as Massachusetts General Hospital, to conduct a Phase I clinical trial evaluating the safety and feasibility of CARV3.TEAM-E cells for the treatment of primary or recurrent glioblastoma (GBM), a deadly brain tumor. The CARV3.TEAM-E cells are genetically engineered chimeric antigen receptor (CAR) T cells that target the...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.353 - 21st Century Cures Act - Beau Biden Cancer Moonshot) provides $699,080 to the Ann & Robert H. Lurie Children's Hospital of Chicago to implement Optical Genome Mapping (OGM) as a first-line diagnostic approach for pediatric brain tumors. The project aims to utilize OGM technology to rapidly identify clinically significant structural variants in pediatric brain tumors that may guide treatment plans for...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...